Clinical Trial Update: Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results evaluate the efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Koselugo (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Neurofibromatosis 1, Plexiform Neurofibroma (PN) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-20